MARKET

XNCR

XNCR

Xencor
NASDAQ
16.52
-0.54
-3.17%
After Hours: 16.26 -0.26 -1.57% 17:18 12/12 EST
OPEN
17.02
PREV CLOSE
17.06
HIGH
17.14
LOW
16.44
VOLUME
507.47K
TURNOVER
--
52 WEEK HIGH
26.59
52 WEEK LOW
6.92
MARKET CAP
1.18B
P/E (TTM)
-8.7709
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Teleflex (TFX) and Xencor (XNCR)
TipRanks · 4d ago
Xencor issued U.S. patent for Xtend Fc domain
TipRanks · 5d ago
Xencor Secures New US Patent, Extending Ultomiris Royalties By Three Years And Unlocking Up To $120M In Additional Revenue
Benzinga · 5d ago
Xencor Extends U.S. Patent Term for Xtend™ Antibodies, Extending Ultomiris Royalties to 2028
Reuters · 5d ago
XENCOR INC - ULTOMIRIS ROYALTY TERM EXTENDED TO 2028 IN U.S.
Reuters · 5d ago
XENCOR INC - ESTIMATES $100 MLN-$120 MLN IN POTENTIAL ROYALTY REVENUE THROUGH 2028
Reuters · 5d ago
Weekly Report: what happened at XNCR last week (1201-1205)?
Weekly Report · 6d ago
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Acadia Healthcare (ACHC)
TipRanks · 12/03 12:00
More
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Webull offers Xencor Inc stock information, including NASDAQ: XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.